Volume 9 Issue 1
Jan.  2018
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2018  >  9(1): 63-68
Sun Yanling, Zhang Jingwen, Fang Zhigang. Efficacy of autologous hematopoietic stem cell transplantation on the treatment of patients with acute myeloid leukemia[J]. ORGAN TRANSPLANTATION, 2018, 9(1): 63-68. doi: 10.3969/j.issn.1674-7445.2018.01.009
Citation: Sun Yanling, Zhang Jingwen, Fang Zhigang. Efficacy of autologous hematopoietic stem cell transplantation on the treatment of patients with acute myeloid leukemia[J]. ORGAN TRANSPLANTATION, 2018, 9(1): 63-68. doi: 10.3969/j.issn.1674-7445.2018.01.009
shu

Efficacy of autologous hematopoietic stem cell transplantation on the treatment of patients with acute myeloid leukemia

doi: 10.3969/j.issn.1674-7445.2018.01.009

  • Department of Hematology, the Third Affiliated Hospital of Sun Yat-sen University, Institute of Hematology of Sun Yat-sen University, Guangzhou 510630, China

More Information
  • Corresponding author: Fang Zhigang, E-mail:fzg92@163.com
  • Received Date: 2017-10-02
    Available Online: 2021-01-19
  • Publish Date: 2018-01-15
    Abstract
  •   Objective  To observe the efficacy of autologous hematopoietic stem cell transplantation on the treatment of patients with acute myeloid leukemia (AML) in complete remission stage.  Methods  Clinical data of 14 AML patients underwent autologous hematopoietic stem cell transplantation were analyzed retrospectively, including 7 low-risk patients, 6 moderate-risk patients and 1 high-risk patient. After pretreatment, pre-cryopreserved autologous peripheral blood stem cells were retransfused. And component blood transfusion, increasing white blood cell (WBC) count and preventing from infection, etc. were given. Hematopoietic reconstitution of autologous stem cells in the patients was observed, and incidence of transplantation related complications was obtained. Furthermore, survival curves were drawn, and postoperative 1-and 3-year overall survival rates and disease-free survival (DFS) rates were calculated.  Results  Hematopoietic reconstitution was achieved in all 14 patients. The median time of WBC implantation was 12(9-28) d, and that of platelet implantation was 29(8-158) d. Two patients suffered from E. coli septicemia during neutropenia stage, 1 from proteus vulgaris septicemia, 1 from cytomegalovirus viremia within 29 d after transplantation and the remaining from infection or gastrointestinal reaction after pretreated. All patients were cured by anti-infection and other symptomatic relief and supportive treatment. All patients were followed up for 29.8(5.3-61.5) months. In 14 patients, 5 cases recurred. 11 patients survived and 3 died of recurrence. The postoperative 1-and 3-year overall survival rates were 86% and 79%, and the postoperative 1-and 3-year DFS rates were 64% and 57%.  Conclusions  Autologous hematopoietic stem cell transplantation is effective in the treatment of majority patients with low-or moderate-risk AML.

     

    • FullText(HTML)
  • loading
    • References(18)
  • [1]
    GORIN NC, GIEBEL S, LABOPIN M, et al. Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? present status and future prospects[J]. Bone Marrow Transplant, 2015, 50 (12): 1495-1502. DOI: 10.1038/bmt.2015.179.
    [2]
    WETZEL D, MUELLER BU, MANSOURI TALEGHANI B, et al. Delayed haematological recovery after autologous stem cell transplantation is associated with favourable outcome in acute myeloid leukaemia[J]. Br J Haematol, 2015, 168(2): 268-273. DOI: 10.1111/bjh.13118.
    [3]
    DOHNER H, ESTEY EH, AMADORI S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net[J]. Blood, 2010, 115(3): 453-474. DOI: 10.1182/blood-2009-07-235358.
    [4]
    HELBIG G, KOCLĘGA A, WOZNICZKA K, et al. Long-term outcome of autologous hematopoietic stem cell transplantation (AHSCT) for acute myeloid leukemia (AML)-single center retrospective analysis[J]. Pathol Oncol Res, 2017, 6(28): 1-7. DOI: 10.1007/s12253-017-0266-7.
    [5]
    USUKI K, KUROSAWA S, UCHIDA N, et al. Comparison of autologous hematopoietie cell transplantation and chemotherapy as postremission treatment in non-M3 acute myeloid leukemia in first complete remission[J]. Clin Lymphoma Myeloma Leuk, 2012, 12(6): 444-451. DOI: 10.1016/j.clml.2012.07.004.
    [6]
    ZUCKERMAN T, ROWE JM. Transplantation in acute myeloid leukemia[J]. Hematol Oncol Clin North Am, 2014, 28(6): 983-994. DOI: 10.1016/j.hoc.2014.08.016.
    [7]
    张之南, 沈悌.血液病诊断及疗效标准[M].3版.北京:科学出版社, 2007:106-116.
    [8]
    VELLENGA E, VAN PUTTER W, OSSENKOPPELE GJ, et al. Autologous peripheral blood stem cell transplantation for acute my eloid leukemia[J]. Blood, 2011, 118 (23): 6037-6042. DOI: 10.1182/blood-2011-07-370247.
    [9]
    GORIN NC, LABOPIN M, FRASSONI F, et al. Identical outcome after autologous or allogeneic genoidentieal hematopoietic stemcell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation[J]. J Clin Oncol, 2008, 26(19): 3183-3188. DOI: 10.1200/JCO.2007.15.3106.
    [10]
    MEHTA J, POWLES R, SINGHAL S, et al. Autologous bone marrow transplantation for acute myeloid leukemia in first remission: identification of modifiable prognostic factors[J]. Bone Marrow Transplant, 1995, 16(4): 499-506.
    [11]
    KORBLING M, FLIEDNER TM, HOLLE R, et al. Autologous blood stem cell (ABSCT) versus purged bone marrow transplantation (pABMT) in standard risk AML: influence of source and cell composition of the autograft on hematopoietic reconstitution and disease-free survival[J]. Bone Marrow Transplant, 1991, 7(5): 343-349. https://oparu.uni-ulm.de/xmlui/handle/123456789/4780
    [12]
    BENSINGER WI, DEEG HJ. Blood or marrow?[J]. Lancet, 2000, 355(9211): 1199-1200. doi: 10.1016/S0140-6736(00)02080-8
    [13]
    CZERW T, LABOPIN M, GORIN NC, et al. Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplnatation[J]. Cancer, 2016, 122(12): 1880-1887. DOI: 10.1002/cncr.29990.
    [14]
    KAYSER S, SCHLENK RF, GRIMWADE D, et al. Minimal residual disease-directed therapy in acute myeloid leukemia[J]. Blood, 2015, 125(15): 2331-2335. DOI: 10.1182/blood-2014-11-578815.
    [15]
    SIMANCIKOVA L, BOJTARAVA E, HRUBISKO M, et al. Autologous hematopoietic stem cell transplantation for acute myeloid leukemia-single center experience[J]. Neoplasma, 2017, 6(8): 512-518. DOI: 10.4149/neo_2017_512.
    [16]
    MIZUTANI M, HARA M, FUJITA H, et al. Comparable outcomes between autologous and allogeneic transplant for adult acute myeloid leukemia in first CR[J]. Bone Marrow Transplant, 2016, 51(5): 645-653. DOI: 10.1038/bmt.2015.349.
    [17]
    曹易耕, 姜尔烈, 何祎, 等.自体外周血造血干细胞移植治疗55例急性髓系白血病患者的疗效及预后分析[J].中华血液学杂志, 2016, 37(6): 464-468. DOI: 10.3760/cma.j.issn.0253-2727.2016.06.005.

    CAO YG, JIANG EL, HE Y, et al. Analyses of outcome and prognostic factors of adult acute myeloid leukemia patients received autologous hematopoietic stem cell transplantation[J]. Chin J Hematol, 2016, 37(6): 464-468. DOI: 10.3760/cma.j.issn.0253-2727.2016.06.005.
    [18]
    丁喆, 韩明哲, 陈书连, 等.86例成人Ph染色体阴性急性B淋巴细胞白血病自体造血干细胞移植疗效及微小残留病检测的临床意义[J].中华血液学杂志, 2015, 36(7): 587-592. DOI: 10.3760/cma.j.issn.0253-2727. 2015.07.013.

    DING Z, HAN MZ, CHEN SL, et al. Outcomes of adults with Ph-negative B-cell acute lymphoblastic leukemia after autologous hematopoietic stem cell transplantation and the significance of minimal residual disease[J]. Chin J Hematol, 2015, 36(7): 587-592. DOI: 10.3760/cma.j.issn.0253-2727.2015.07.013.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (364) PDF downloads(15) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return